GSK plc
NYSE:GSK · New York Stock Exchange
-$1.34 today
Vol 4.22M · Avg 4.07M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:GSK · Revenue to Net Income
Key Ratios
Analysis
$32.8B of revenue converted into $5.8B of net income for the selected period. Gross margin is 72.8% and net margin is 17.9%, showing how much revenue survives after costs and taxes. EPS is $3.36, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $32.7B +4.1% | $31.4B +3.5% | $30.3B +3.4% | $29.3B +18.7% | $24.7B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $9.0B -0.3% | $9.0B +5.6% | $8.6B -10.4% | $9.6B +17.0% | $8.2B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $23.6B +5.9% | $22.3B +2.6% | $21.8B +10.1% | $19.8B +19.6% | $16.5B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 72.4% +1.2pp | 71.2% -0.6pp | 71.8% +4.3pp | 67.4% +0.5pp | 66.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $7.5B +17.6% | $6.4B +2.9% | $6.2B +13.4% | $5.5B +9.3% | $5.0B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $9.1B -17.5% | $11.0B +17.4% | $9.4B +12.1% | $8.4B +18.4% | $7.1B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $15.3B -16.4% | $18.3B +21.9% | $15.0B +12.6% | $13.3B +9.5% | $12.2B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.3B -9.3% | $2.6B +11.2% | $2.3B +6.8% | $2.1B +1.2% | $2.1B | $374.2M | $1.2B | $631.8M |
| EBITDA | $10.4B +56.0% | $6.7B -26.6% | $9.1B +5.6% | $8.6B +32.6% | $6.5B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 31.8% +10.6pp | 21.3% -8.7pp | 29.9% +0.6pp | 29.3% +3.1pp | 26.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | $8.3B +107.4% | $4.0B -40.4% | $6.7B +4.8% | $6.4B +47.6% | $4.4B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 25.5% +12.7pp | 12.8% -9.4pp | 22.2% +0.3pp | 21.9% +4.3pp | 17.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $56.0M -16.9% | $67.4M +68.5% | $40.0M -37.8% | $64.3M +129.5% | $28.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $687.0M +4.5% | $657.6M -15.2% | $775.0M -9.4% | $855.5M +9.1% | $784.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$937.0M -72.2% | -$544.0M +20.1% | -$681.0M +15.4% | -$805.0M -6.2% | -$758.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $7.4B +112.9% | $3.5B -42.7% | $6.1B +7.7% | $5.6B +56.4% | $3.6B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 22.7% +11.6pp | 11.1% -8.9pp | 20.0% +0.8pp | 19.2% +4.6pp | 14.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $1.1B +111.4% | $526.0M -30.4% | $756.0M +6.9% | $707.0M +751.8% | $83.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | $5.7B +122.0% | $2.6B -47.7% | $4.9B -67.1% | $15.0B +241.1% | $4.4B | $4.9B | $4.8B | $4.7B |
| Net Margin | 17.5% +9.3pp | 8.2% -8.0pp | 16.2% -34.8pp | 51.0% +33.2pp | 17.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $6 +347.6% | $1 -48.4% | $2 -67.2% | $7 +171.5% | $3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $6 +348.4% | $1 -48.3% | $2 -67.2% | $7 +171.1% | $3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $1.0B -50.3% | $2.0B +0.6% | $2.0B +0.6% | $2.0B +25.7% | $1.6B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $1.0B -50.3% | $2.1B +0.8% | $2.1B +0.7% | $2.0B +26.0% | $1.6B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
CVS Health Corporation
NYSE:CVS
$125.44B
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
$114.73B
Bristol-Myers Squibb Company
NYSE:BMY
$109.97B
Sanofi
NASDAQ:SNY
$101.42B
McKesson Corporation
NYSE:MCK
$87.79B
Elevance Health Inc.
NYSE:ELV
$84.22B
HCA Healthcare, Inc.
NYSE:HCA
$83.31B
Cigna Corporation
NYSE:CI
$74.29B
Zoetis Inc.
NYSE:ZTS
$32.77B
Bristol-Myers Squibb Company Ce
CELG-RI
$245.05M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does GSK generate?
GSK plc (GSK) reported $32.67B of revenue in fiscal 2025.
Is GSK profitable?
GSK plc (GSK) reported $5.72B of net income, with a net margin of 17.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.